Publications by authors named "Yuechan Ma"

Acute myeloid leukemia (AML) is a clonal malignancy originating from leukemia stem cells, characterized by a poor prognosis, underscoring the necessity for novel therapeutic targets and treatment methodologies. This study focuses on Ras homolog family member F, filopodia associated (RHOF), a Rho guanosine triphosphatase (GTPase) family member. We found that RHOF is overexpressed in AML, correlating with an adverse prognosis.

View Article and Find Full Text PDF

CCAAT/enhancer binding protein α (C/EBPα) regulates myeloid differentiation, and its dysregulation contributes to acute myeloid leukaemia (AML) progress. Clarifying its functional implementation mechanism is of great significance for its further clinical application. Here, we show that C/EBPα regulates AML cell differentiation through liquid-liquid phase separation (LLPS), which can be disrupted by C/EBPα-p30.

View Article and Find Full Text PDF

Background: Chemotherapy is still the standard regimen for treating acute myeloid leukemia (AML) and its disappointing efficacy requires the urgent need for new therapeutic targets. It is well known that immune response plays an increasingly significant role in the pathogenesis of AML.

Methods: We detected nine single nucleotide polymorphisms (SNPs) in immune checkpoint-related genes, including PD1, LAG3, TIM3, and TIGIT in 285 AML inpatients and 324 healthy controls.

View Article and Find Full Text PDF
Article Synopsis
  • Acute myeloid leukemia (AML) is a complex cancer of the blood, and this study examines the role of genetic variations, specifically KLK2 SNPs rs198977 and rs2664155, in its development.* -
  • The research involved comparing 284 AML patients with 280 healthy individuals to determine the association between KLK2 SNPs and AML risk, finding that the TT genotype of rs198977 increased AML susceptibility and hyperleukocytosis risk.* -
  • While the study highlights KLK2 rs198977 as a potential genetic marker for AML, it found no significant link between the other SNP (rs2664155) and the disease, suggesting new possibilities for understanding AML and future treatment options
View Article and Find Full Text PDF

Background: Although anthracyclines are the first-line chemotherapy drugs for treating non-M3 acute myeloid leukaemia (AML), their efficacy remains limited. It is important to identify factors that influence the efficacy of anthracyclines against AML. Mitochondrial apoptosis-related genes play significant roles in the pathogenesis, treatment, and prognosis of AML.

View Article and Find Full Text PDF